Shidlovski / Shutterstock.com
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
As compound patents and regulatory data protection for medicinal products expire, pharmaceutical companies increasingly look to develop new uses for their products. This strategy usually involves filing second medical use patents to protect the invention and research investment.
As well as the complex patent landscape that surrounds such patents, and any extension to regulatory marketing protection that may be available, several regulatory and practical factors may impact how well second uses for existing products can be protected from immediate generic competition.
When assessing a generic medicinal product, the competent authorities generally require the same information to appear in the summary of product characteristics (SmPC) and other product information of the generic medicine, as for the original, reference medicine.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Arnold & Porter, second medical use, patent holders, data protection, generics, SmPC, INN, CJEU, healthcare, pharmaceuticals, English High Court